Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
